---
document_datetime: 2025-12-15 14:34:52
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/coagadex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: coagadex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.4640667
conversion_datetime: 2025-12-25 01:21:34.912896
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Coagadex

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                                      | Scope                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Marketing Authorisation Transfer - H / EMA/T/0000302442 | - Transfer of a marketing authorisation - transfer of marketing authorisation from BPL | 24/10/2025                          | 21/11/2025                                  | SmPC, Labelling and              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                          | Bioproducts Laboratory GmbH to Kedrion S.p.A.                                                                                                                                                                                                                                                         |            |            | PL   |                   |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------|
| Variation type IA_IN /                   | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted | 21/07/2025 | N/A        |      | EMA/VR/0000287079 |
| Variation type IA_IN / EMA/VR/0000286201 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted | 16/07/2025 | N/A        |      |                   |
| Article 61(3) / EMA/N/0000282603         | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives.                                                                                                                                                                     | 15/07/2025 | 21/11/2025 | PL   |                   |
| Variation type II / EMA/VR/0000264724    | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.II.d.2 Change in test procedure for the                                                                                                    | 19/06/2025 | 21/11/2025 |      |                   |

<div style=\"page-break-after: always\"></div>

| finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.II.d.2 Change in test procedure for the   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000275727 | This was an application for a group of variations. B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                | 03/06/2025 | N/A |
| Variation type IB / EMA/VR/0000265336 | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 30/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN /                   | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted   | 08/04/2025   | N/A        |    | EMA/VR/0000263378   |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|---------------------|
| Variation type IA_IN / EMA/VR/0000255934 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted   | 07/03/2025   | N/A        |    |                     |
| Article 61(3) / EMA/N/0000247523         | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4.                                        | 04/03/2025   | 21/11/2025 | PL |                     |
| Variation type IA / EMA/VR/0000249722    | B.II. FINISHED PRODUCT - B.II.z The information in 3.2.A.1 has to be changed as in the provided floor plans an indicated                                                                                                                                                                                | 04/03/2025   | N/A        |    |                     |

<div style=\"page-break-after: always\"></div>

|                                          | meeting room will be changed to a storage room - Refused                                                                                                                                                                                                                                              |            |     |                   |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB /                      | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                              | 27/02/2025 | N/A | EMA/VR/0000247762 |
| Variation type IA_IN / EMA/VR/0000247536 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted | 13/02/2025 | N/A |                   |
| Variation type IB / EMA/VR/0000244811    | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted | 12/02/2025 | N/A |                   |